e8vk
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 7, 2009
 
CYCLACEL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction
of incorporation) 		  0-50626
(Commission File Number) 		  91-1707622
(IRS Employer
Identification No.)
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (908) 517-7330
 
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

TABLE OF CONTENTS

Item 8.01 Other Events
Item 9.01 Financial Statements and Exhibits
SIGNATURES
Item 8.01   Other Events
     On May 7, 2009, Cyclacel Pharmaceuticals, Inc. (the “Company”) issued a press release announcing various upcoming corporate events and that the Company will announce its first quarter 2009 financial results on Thursday, May 14, 2009 and host a conference call and live webcast at 4:30 p.m. Eastern on the same day. Attached as Exhibit 99.1 is a copy of the press release.
Item 9.01   Financial Statements and Exhibits
(d)   The following exhibit is furnished with this Report:
         
Exhibit No.   Description
       
 
  99.1    
Press Release dated May 7, 2009

 

 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
         
  CYCLACEL PHARMACEUTICALS, INC.
 		  
  By:   /s/ Paul McBarron    
    Name:   Paul McBarron   
    Title:   Executive Vice President—Finance,
Chief Financial Officer and
Chief Operating Officer 		  
 
Date: May 7, 2009